Antipsychotic agents: A survey of the prevalence, severity and burden of side effects

International Clinical Psychopharmacology

Volumn 11, Issue 1, 1996, Pages 1-12

  Bhavnani, S M ^a   Levin, G M ^b,c  

^a MILLARD FILLMORE HOSPITAL   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c NONE   (United States)

Author keywords

antipsychotic agents; patient related burden; severity; side effects

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; THIORIDAZINE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; SKIN TOXICITY;

EID: 0029937945     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199603000-00001     Document Type: Article

References (32)

1. Abuzzahab FS and Zimmerman RL (1982) Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. Journal of Clinical Psychiatry, 43, 105-110.
2. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised. APA, Washington, DC.
3. Angst J and Woqqon B (1975) Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazinedecanoate, fluspirilene, penfluridol, perphenazineenanthate and pipothiazinepalmitate. Arzneimittelforschung, 25, 267-270.
4. Awad GA (1992) Quality of life of schizophrenic patients on medications and implications for new drug trials. Hospital and Community Psychiatry, 43, 262-265.
5. Baldessarini RJ, Katz B and Cotton P (1984) Dissimilar dosing with high-potency and low-potency neuroleptics. American Journal of Psychiatry, 141, 748-752.
6. Ban TA, Lehmann HE, Sterlin C and Climan M (1975) Comprehensive clinical studies with thiothixene. Diseases of the Nervous System, 36, 473-477.
7. Bauer D and Gaertner HJ (1983) Effects of neuroleptics on liver function, the hematopoietic system, blood pressure and temperature regulation. Comparison of clozapine, perazine and haloperidol by evaluating medical records. Pharmacopsychiatria, 16, 23-29.
8. Bressler B and Friedel RO (1971) A comparison between chlorpromazine and thiothixene in a Veterans Administration hospital population. Psychosomatics, 12, 275-277.
9. Carney MW and Sheffield BF (1976) Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia. British Journal of Psychiatry, 129, 476-481.
10. Crismon ML and Dorson PG (1992) Schizoprenia. In: Pharmacotherapy - A Pathophysiologic Approach (Ed. JT DiPiro), pp. 1020-1043. Elsevier Science, New York.
11. Davidhizar RE (1985) Can clients with schizophrenia describe feelings and beliefs about taking medications? Journal of Advanced Nursing, 10, 469-473.
12. Davis JM (1976) Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry, 33, 858-861.
13. Halstead SM, Barnes TRE and Speller JC (1994) Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. British Journal of Psychiatry, 164, 177-183.
14. Heresco-Levy U, Brom D and Greenberg D (1993) Self-reported prescribing practices for schizophrenic patients among Israeli psychiatrists. Israel Journal of Psychiatry and Related Sciences, 30, 164-174.
15. Hirsch SR and Barnes TRE (1994) Clinical use of high-dose neuroleptics. British Journal of Psychiatry, 164, 94-96.
16. Huskisson EC (1983) Visual analog scales. In: Pain Management and Assessment (Ed. R Melzack), pp. 33-37. Raven Press, New York.
17. Kane JM (1985) Antipsychotic drug side effects: their relationship to dose. Journal of Clinical Psychiatry, 46 (5, Pt 2), 16-21.
18. Kane JM (1989) The current status of neuroleptic therapy. Journal of Clinical Psychiatry, 50, 322-328.
19. Kane JM, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry, 45, 789-796.
20. Lehman AF and Burns BJ (1990) Severe mental illness in the community. In: Quality of Life Assessments in Clinical Trials (Ed. B Spilker), pp. 357-366. Raven Press, New York.
21. Levinson DF (1991) Pharmacologic treatment of schizophrenia. Clin Ther, 13, 326-352.
22. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS and Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Quality of Life Research, 1, 331-340.
23. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ and Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica, 76 (Suppl 334), 81-100.
24. Pennington JAT and Nichols-Church H (Eds) (1985) Bowes and Churches's Food Values and Portions, 14th edn, pp. 223-224. JP Lippincott, Philadelphia.
25. Realmuto GM, Erickson WD, Yellin AM, Hopwood JA and Greenberg LM (1984) Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. American Journal of Psychiatry, 141, 440-442.
26. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL and Mendels J (1990) Antidepressant efficacy of sertraline: double-blind, placebo-and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. Journal of Clinical Psychiatry, 51 (Suppl B), 18-27.
27. Reviil SL, Robinson JO, Rosen M and Hoggs MIJ (1976) The reliability of a linear analogue for evaluating pain. Anaesthesia, 31, 1191-1198.
28. Simpson GM, Pi EH and Sramek JJ Jr (1981) Adverse effects of antipsychotic agents. Drugs, 21, 138-151.
29. Spilker B (1990) Introduction. In: Quality of Life Assessments in Clinical Trials (Ed. B Spilker), pp. 3-9. Raven Press, New York.
30. van Dam FS, Somers R and van-Beek-Couzijn AL (1981) Quality of life: some theoretical issues. Journal of Clinical Pharmacology, 21 (Suppl), 1665-1685.
31. Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs. Archives of General Psychiatry, 31, 67-72.
32. Wyatt RJ (1976) The neuroleptics - their mechanism of action: a review of the biochemical literature. Psychopharmacology Bulletin, 12, 5-50.